Replies to post #33755 on Ocata Therapeutics Inc fka OCAT

[rocky301]

There was a mention, I believe made by Rabin, I believe, that within a year, the commercial prospects, i.e. revenue for ACTC, will compare to and surpass Lipitor.

On the contrary, at yesterdays meeting he specifically stated that any significant revenues won't happen for "a couple of few years out" and that most likely will be with compassionate use, possibly in Europe. The commercial side of the money maker dryAMD(Lipitor numbers) are further out yet.

23:50 time mark here:
http://www.wsw.com/webcast/rrshq20/actc/

[ddls]

They will "try" to avoid a RS if at all possible. But, RS'S have to be put into two categories, 1. those that do it out of necessity to stay on a certain exchange, and 2. those that do it on strength. ACTC would do it on the latter. ACTC will be the next "Google" of biotech, and then some. Here's to ACTC. Cheers!